OBIO — Orchestra Biomed Holdings Share Price
Last trade - 00:00- $166.01m
- $78.41m
- $2.76m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.44 | ||
| Price to Tang. Book | 2.44 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 60.15 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -62.68% | ||
| Return on Equity | -81.47% | ||
| Operating Margin | -1907.86% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | 5.7 | -0.78 | 3.53 | 2.76 | 3.87 | 3.9 | -21.49% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Orchestra BioMed Holdings, Inc. is a biomedical innovation company seeking to provide solutions for unmet needs in procedure-based medicine. The Company’s flagship product candidates are Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of artery disease, the leading cause of mortality worldwide, and BackBeat Cardiac Neuromodulation Therapy (BackBeat CNT) for the treatment of hypertension, a significant risk factor for death worldwide. Virtue SAB is a drug/device combination product candidate for the treatment of artery disease designed to deliver an extended-release formulation of sirolimus, SirolimusEFR, during balloon angioplasty without the need for balloon coating or a permanent implant. BackBeat CNT is a bioelectronic treatment for hypertension that is designed to drive an immediate, substantial and persistent reduction in blood pressure while simultaneously modulating autonomic nervous system responses to maintain the reduction.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- January 25th, 2023
- Public Since
- August 4th, 2020
- No. of Shareholders
- 595
- No. of Employees
- 56
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 35,777,412
- Address
- 150 Union Square Drive, NEW HOPE, 18938
- Web
- Phone
- +1 6463439298
- Auditors
- Ernst & Young LLP
Upcoming Events for OBIO
Similar to OBIO
908 Devices.
NASDAQ Global Market
Alpha Teknova
NASDAQ Global Market
AtriCure
NASDAQ Global Market
Brainsway
NASDAQ Global Market
Castle Biosciences
NASDAQ Global Market
FAQ
As of Today at 19:16 UTC, shares in Orchestra Biomed Holdings are trading at $4.64. This share price information is delayed by 15 minutes.
Shares in Orchestra Biomed Holdings last closed at $4.64 and the price had moved by -69.27% over the past 365 days. In terms of relative price strength the Orchestra Biomed Holdings share price has underperformed the S&P500 Index by -74.43% over the past year.
The overall consensus recommendation for Orchestra Biomed Holdings is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Orchestra Biomed Holdings does not currently pay a dividend.
Orchestra Biomed Holdings does not currently pay a dividend.
Orchestra Biomed Holdings does not currently pay a dividend.
To buy shares in Orchestra Biomed Holdings you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $4.64, shares in Orchestra Biomed Holdings had a market capitalisation of $166.01m.
Here are the trading details for Orchestra Biomed Holdings:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: OBIO
Based on an overall assessment of its quality, value and momentum Orchestra Biomed Holdings is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Orchestra Biomed Holdings is $16.33. That is 251.94% above the last closing price of $4.64.
Analysts covering Orchestra Biomed Holdings currently have a consensus Earnings Per Share (EPS) forecast of -$1.60 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Orchestra Biomed Holdings. Over the past six months, its share price has underperformed the S&P500 Index by -22.91%.
As of the last closing price of $4.64, shares in Orchestra Biomed Holdings were trading -30.02% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Orchestra Biomed Holdings PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $4.64.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Orchestra Biomed Holdings' directors